SBIR/STTR Research Award
2-5A ANTISENSE INHIBITION OF RESPIRATORY SYNCYTIAL VIRUS
Award amount
$99,875Program and phase
SBIR · Phase IAward year
1999Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Not reported
- Recipient company
- GEMINI TECHNOLOGIES, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
Not Available This Phase I Proposal aims to maximize gene transfer by means of polymeric-based micellar and nanoparticulate delivery vehicles in order to elicit protective immunity against Brucella. In-vitro cell mediated cytotoxicity and in-vivo pathogen protection in a challenge test will be demonstrated. For Phase I Option we will further characterize the protective immunity by means of cellular and humoral responses and analyze the protective effect over an extended period of time. BENEFITS: Development of protective (and therapeutic) vaccine against Brucella as a commercial product
Technology keywords
Not reported